Depression and suicidality with VMAT2 inhibitors in tardive dyskinesia A signal detection from the FDA Adverse Events Reporting System

被引：0
|
作者：
Yokoi, Yuma [1 ,2 ]
Kashiwagi, Hiroko [3 ]
Funada, Daisuke [3 ]
Yamashita, Shingo [2 ]
Kubota, Chika [2 ]
机构：
[1] Natl Ctr Hosp, Natl Ctr Neurol & Psychiat, Clin Res & Educ Promot Div, Dept Educ Promot, Tokyo, Japan
[2] Natl Ctr Hosp, Natl Ctr Neurol & Psychiat, Dept Psychiat, Tokyo, Japan
[3] Natl Ctr Hosp, Natl Ctr Neurol & Psychiat, Dept Forens Psychiat, Tokyo, Japan
来源：
PSYCHIATRY AND CLINICAL NEUROSCIENCES REPORTS | 2023年 / 2卷 / 01期
关键词：
D O I：
10.1002/pcn5.79
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Neurological adverse events associated with esketamine: A disproportionality analysis for signal detection leveraging the FDA adverse event reporting system (vol 13, 849758, 2022)
    Guo, Haoning
    Wang, Bin
    Yuan, Shuying
    Wu, Silin
    Liu, Jing
    He, Miaoquan
    Wang, Jisheng
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [32] SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
    Gian Paolo Fadini
    Benedetta Maria Bonora
    Angelo Avogaro
    Diabetologia, 2017, 60 : 1385 - 1389
  • [33] SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System
    Fadini, Gian Paolo
    Bonora, Benedetta Maria
    Avogaro, Angelo
    DIABETOLOGIA, 2017, 60 (08) : 1385 - 1389
  • [34] Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database
    Contreras-Salinas, Homero
    Romero-Lopez, Maria Soledad
    Olvera-Montano, Oscar
    Rodriguez-Herrera, Lourdes Yolotzin
    BMJ OPEN OPHTHALMOLOGY, 2024, 9 (01):
  • [35] Mechanism of action of vesicular monoamine transporter 2 (VMAT2) inhibitors in tardive dyskinesia: reducing dopamine leads to less "go" and more "stop" from the motor striatum for robust therapeutic effects
    Stahl, Stephen M.
    CNS SPECTRUMS, 2018, 23 (01) : 1 - 6
  • [36] SGTL2 inhibitors and amputations in the US FDA Adverse Event Reporting System
    Fadini, Gian Paolo
    Avogaro, Angelo
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (09): : 680 - +
  • [37] Comparing pharmacologic mechanism of action for the vesicular monoamine transporter 2 (VMAT2) inhibitors valbenazine and deutetrabenazine in treating tardive dyskinesia: does one have advantages over the other?
    Stahl, Stephen M.
    CNS SPECTRUMS, 2018, 23 (04) : 239 - 247
  • [38] Cardiovascular adverse events associated with norepinephrine-dopamine reuptake inhibitors: a pharmacovigilance study of the FDA Adverse Event Reporting System
    Kandukuru, Abhishek
    Sharma, Priyanka
    Gupta, Sheeba Verghese
    Nkembo, Augustine
    Sutariya, Vijaykumar
    CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2024, 102 (12) : 709 - 719
  • [39] A DISPROPORTIONALITY ANALYSIS OF SPONTANEOUS ADVERSE EVENT REPORTS FOR OSTEONECROSIS OF JAW ATTRIBUTED TO AROMATASE INHIBITORS IN FDA ADVERSE EVENTS REPORTING SYSTEM
    Reddy, Ravindra N.
    Viswam, S. K.
    Thomas, B. E.
    Bellapu, A.
    Sharma, V
    Chacko, S.
    VALUE IN HEALTH, 2019, 22 : S613 - S613
  • [40] Gastrointestinal adverse events associated with PI3K inhibitors: A disproportionality analysis of FDA adverse event reporting system
    Viswam, Subeesh Kulangara
    Kamath, Raksha
    Sharon, Jovita
    Shivakumar, Adithya
    Shenoy, Anjana
    Lukose, Lipin
    Kaur, Gursimran
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 454 - 455
12345